Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether LCZ696 (valsartan/sacubitril) is safe and has beneficial effects on the heart and blood vessels in patients with high blood pressure and/or diabetes or other risk factors for developing heart failure (elevated levels of natriuretic peptide and elevated left atrial volume index). Patients will be randomized to receive LCZ696 or valsartan (and matching placebo) for 18 months to assess the impact on left ventricular diastolic function.


Clinical Trial Description

The STOP-HF prospective, randomized trial demonstrated that a biomarker driven strategy of natriuretic peptide (NP) based screening and collaborative care with general practice can help target cardiovascular prevention and improve outcome in an at-risk population of patients without heart failure.

However, while successful, the STOP-HF biomarker strategy lacks a specific pharmacological intervention linked to the screening biomarker, NP. The most appropriate therapy to build on STOP-HF is LCZ696 (sacubitril/valsartan), a first in class angiotensin receptor neprilysin inhibitor (ARNI). As neprilysin degrades biologically active NP, LCZ696 increases myocardial cyclic guanosine monophosphate (cGMP) while reducing myocardial stiffness and hypertrophy. NPs also stimulate natriuresis, diuresis, vasodilation and have been shown to have anti-fibrotic and anti-sympathetic benefits which could augment the STOP-HF preventative strategy.

Elevated NP in an at-risk population independently identifies cardiovascular risk, which can be specifically targeted by LCZ696. In a small number of patients (4%) with cardiovascular risk factors and elevated NP, significant asymptomatic LV systolic dysfunction will be present and for these RAAS modifying therapy is mandated.

However, there is a larger group of patients with elevated NP who have normal systolic function of the left ventricle but who have significant isolated diastolic dysfunction. These patients have asymptomatic left ventricular diastolic dysfunction (ALVDD) and are at heightened risk for heart failure and other cardiovascular events. The Investigators and others, have shown that cardiac inflammation, fibrosis and hypertrophy drive the pathophysiology. Importantly, there is currently no specific therapy for these patients, beyond conventional risk factor control.

Interrupting this pathophysiological process at an early stage before the development of ventricular dysfunction, may prevent/slow development to heart failure and also have an impact on the development of other cardiovascular events driven by this pathophysiological process. This represents a novel way to modify risks at an earlier stage in the natural course of cardiovascular disease, in a targeted and individualized manner. It is known that suppressing the RAAS will reduce the pro-fibrotic impact of angiotensin II. Addition of neprilysin inhibitor sacubitril in LCZ696, will reduce degradation of endogenous, cardio-protective, biologically active NPs and cGMP and will augment the beneficial impact on fibro-inflammation beyond conventional RAAS modifying therapy.

There are a number of emerging biochemical and imaging surrogates of left ventricular dysfunction, which can be evaluated in a relatively small population over a short time frame in a prospective, phase II study design. Of these, one of the most reliable, continuous markers of diastolic function in the heart is LAVI. There was a dramatic impact of LCZ696 on LAVI in comparison with valsartan in the PARAMOUNT study. Furthermore, this endpoint can be precisely defined using cardiac magnetic resonance imaging (cMRI) in a phase II design. In this study, doppler Echocardiographic images will be collected to correlate with cMRI images. Doppler Echocardiography will be more feasible in follow on studies with larger populations.

In summary, it has been demonstrated that asymptomatic patients with elevated NP levels are at higher risk of heart failure and other cardiovascular events. Elevated NP in this setting represents a protective, endogenous response to fibro-inflammation. The predominant cardiac abnormality in these patients is ALVDD, which can be tracked using LAVI. The hypothesis is that augmenting this protective fibro-inflammatory response with LCZ696 could demonstrate superiority over the current state of art therapy in patients with hypertension or diabetes and elevated NP in a phase II study design and, in doing so, PARABLE may deliver a major clinical innovation in the prevention of cardiovascular disease. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02682719
Study type Interventional
Source The Heartbeat Trust
Contact Kenneth McDonald, MD, FRCPI
Phone 0035312713071
Email kenneth.mcdonald@ucd.ie
Status Recruiting
Phase Phase 2
Start date December 2015
Completion date December 2018

See also
  Status Clinical Trial Phase
Recruiting NCT04558450 - Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN) N/A
Recruiting NCT02499601 - CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD) N/A
Completed NCT01775865 - Targeting Inflammation to Treat Cardiovascular Aging Phase 2
Terminated NCT01188369 - Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy Phase 4
Recruiting NCT05552521 - Diastolic Dysfunction in Septic Shock and Cardiomyopathy Genetic Variants
Recruiting NCT05438030 - Diastolic Function Assessment With Cardiac Magnetic Resonance Imaging N/A
Completed NCT04128735 - Diastolic Dysfunction in Morbidly Obese Patients Undergo Bariatric Surgery
Completed NCT00689819 - Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients N/A
Recruiting NCT04149990 - Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI Phase 2
Completed NCT03768752 - Diastolic Dysfunction and Interstitial Lung Edema in Septic Patients
Completed NCT02932436 - Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics Phase 4
Recruiting NCT05847244 - The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction Phase 2
Enrolling by invitation NCT04190420 - The Transition From Hypertension to Hypertensive Heart Disease and Heart Failure, the PREFERS Hypertension Study
Completed NCT04114474 - Pre-operative Focused Transthoracic Echocardiography for Prediction of Post-operative Cardiac Complications
Not yet recruiting NCT06131008 - Diastology-Guided Management of Decompensated Heart Failure N/A
Completed NCT03110614 - Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of COPD
Not yet recruiting NCT02285309 - Perioperative Measurements of Diastolic Function in Cardiac Surgery N/A
Completed NCT01761318 - Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Phase 4
Completed NCT00907439 - Study of the Effect of Inhaled Anesthetics on Diastolic Heart Function Using a Doppler-derived Efficiency Index N/A
Completed NCT00804518 - Effect of Exercise on Heart Function in Healthy Elderly People N/A